Cardiotonic drugs constitute a pharmaceutical class aimed at augmenting the contractile strength of the heart muscle and enhancing its pumping efficiency. This category of medications plays a pivotal role in addressing diverse cardiovascular conditions, particularly heart failure. Their mechanism involves bolstering the vigor of each cardiac contraction, ultimately improving cardiac output and ensuring efficient blood circulation throughout the body. Notable examples of cardiotonic drugs include milrinone and dobutamine, which work by influencing specific pathways to enhance myocardial contractility. The application of cardiotonic drugs is meticulously monitored due to their narrow therapeutic window and the potential for adverse effects. In contemporary medical practice, these medications are often integrated into comprehensive treatment plans, frequently alongside other cardiovascular drugs, to optimize therapeutic outcomes for individuals with various heart-related disorders.
Title : Revolutionizing CKD care: How finerenone transforms outcomes in heart and kidney health - Insights from fidelio-DKD
Robert J Chilton, University of Texas Health Science Center San Antonio, United States
Title : Novel important cellular responses, signaling mechanisms and therapeutic options for pulmonary hypertension and right heart failure
Yong Xiao Wang, Albany Medical Center, United States
Title : Preventing sports-related cardiac arrest: Coronary artery calcium scoring stratifies the benefit of low-dose aspirin use for risk reduction
Arthur J Siegel, Massachusetts General Hospital, United States
Title : Empathy and precision: Revolutionizing communication between cardiologists and patients
Iris Panagiota Efthymiou, University of Greenwich, United Kingdom
Title : Post-cardiotomy ECMO (PC-ECMO)
Gustavo Lionel Knop, Mayo Clinic, United States
Title : The past, present and future of AI in cardiology
Narendra Kumar, HeartbeatsZ Academy, United Kingdom